The guests have been compensated by AstraZeneca for their participation. The views expressed are their own and do not necessarily reflect those of the AMJ or AstraZeneca. If you choose to act on information discussed here, you do so at your own discretion.
As homologous recombination deficiency (HRD) testing becomes increasingly embedded in ovarian cancer pathways, clinicians need clear, operational guidance. This episode brings together expert perspectives on selecting tests, understanding outputs, and integrating results into guideline-aligned care.
Learn:
- HRD basics in plain language: what you’re measuring and why
- Test selection and reporting nuances that affect downstream decisions
- Workflow design across oncology, pathology, and genetics
- Applying results to maintenance strategies and patient conversations
Speakers:
Rebecca Arend1
Thomas Krivak2
Bhavana Pothuri3
1. Associate Director for Clinical Research, UAB O’Neal Comprehensive Cancer Center; Endowed Professor of Gynecologic Oncology, University of Alabama, USA
2. Director, Division of Gynecologic Oncology; Chief Surgeon, West Penn Hospital, USA
3. Gynecologic Oncologist, NYU Langone Health; Associate Professor, Department of Obstetrics and Gynecology, NYU Grossman School of Medicine, USA
